Blood test could predict prostate cancer drug success
NCT ID NCT02125617
Summary
This study aimed to see if measuring a specific protein in the blood (called uPAR) could help predict which men with advanced prostate cancer would respond well to the drug abiraterone. It involved a very small group of patients whose cancer had progressed despite other treatments. The study was terminated early, so its findings are limited.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATIC NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospital of Copenhagen, Rigshospitalet
Copenhagen, 2100, Denmark
Conditions
Explore the condition pages connected to this study.